Incyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopeful [CNBC]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: CNBC
The future of cancer immunotherapy looks promising, but it suffered a major setback on Friday. Incyte announced that its trial drug epacadostat did not help melanoma patients, and the company is halting the study altogether. Epacadostat was supposed to work in conjunction with Merck's blockbuster cancer immunotherapy drug Keytruda — which has delivered billions in revenue to the pharmaceutical giant — to help the immune system fight cancer. The immune system contains T cells. These cells know the difference between a normal cell they should leave alone and a foreign cell they should attack. The problem is many cancer cells also look normal to T cells. Keytruda helps T cells recognize and fight cancer cells. Drugs like Keytruda are called checkpoint inhibitors. Epacadostat was supposed to further immunotherapy. The body contains an enzyme called IDO , which stops T cells from doing their job. Epacadostat is an IDO inhibitor, meaning it stops IDO from suppressing T
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 [Yahoo! Finance]Yahoo! Finance
- Merck's Future Brightens With Winrevair's Blockbuster Potential [Seeking Alpha]Seeking Alpha
- Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position [Yahoo! Finance]Yahoo! Finance
- Merck Drug for Rare Form of High Blood Pressure Gets US Nod [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 3/19/24 - Form S-3ASR
- 3/19/24 - Form S-3ASR
- 2/26/24 - Form 10-K
- MRK's page on the SEC website